Target organ damage related gene evaluation using olmesartan in hypertensive patients with diabetes mellitus

Trial Profile

Target organ damage related gene evaluation using olmesartan in hypertensive patients with diabetes mellitus

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 May 2017

At a glance

  • Drugs Olmesartan medoxomil (Primary)
  • Indications Diabetic nephropathies; Hypertension
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms TOGETHER
  • Most Recent Events

    • 04 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top